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Abstract
Cerebral ischemia is known to induce cell death through hypoxia and oxidative stress
following reperfusion. However, cell death can spread beyond the ischemic core when toxic
glutamate levels act on NMDA receptors of surrounding regions. Levels of CXCL12, a
chemokine primarily released from glia, reportedly elevate following ischemia. Acute
activation of its receptor, CXCR4, appears to serve a neuroprotective function while
prolonged activation results in cell death and this cell death was reported to be dependent on
the combined release of calcium from intracellular stores as well as calcium influx through
NMDARs. Calcium influx through NMDA receptor channels leads to activation of CaMKII,
and it has also been shown that intracellular calcium can be sufficient to activate CaMKII.
Thus, it is of interest to determine if cell death following CXCL12 application is mediated by
CaMKII; and further, if exposure to CXCL12 primes neurons for glutamate-induced toxicity
thus increasing cell death. Here, it was confirmed that acute (30 min) delivery of CXCL12 is
not detrimental, while sustained activation (3 hour) resulted in a significant increase in cell
death compared to controls. In addition, both acute and sustained CXCL12 exposure induced
translocation of CaMKII to synapses. Delivery of a strong excitatory stimulus (500 µM glu +
10 µM gly) following either acute or sustained CXCL12 application appeared to elevate
susceptibility to glutamate-induced cell death. Interestingly, pre-exposure to CXCL12 also
induced cell death following delivery of a more physiologically relevant concentration of
glutamate (100 µM glu + 10 µM gly). Peptide inhibitors that act to block CaM or ATP
binding to CaMKII both appeared to reduce CXCL12-induced increases in cell death. These
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results suggest that both acute and sustained CXCR4 activation increase neuron susceptibility
to excitotoxicity and this priming is at least partially mediated by CaMKII.
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Chapter 1: Introduction

Introduction
Cerebral ischemic attack, commonly referred to as stroke, is the leading cause of
disability, the second leading cause of dementia and the third leading cause of death
worldwide (Bakhai, 2010). Due to this high prevalence, it is critical to determine the
underlying mechanisms and causes of stroke-induced cell death. Interestingly, there is strong
evidence that genetic factors influence the pathogenesis of stroke, but discovery of specific
mutations has been limited (Hassan and Markus, 2000). Behavioral risk factors and
preventative measures for stroke are fairly well defined; however, there is still a lack of
awareness and a lack of emphasis of the behavioral factors which has led to the high stroke
rates and problems associated with them (Gorelick, 2002). As clinicians continue to try and
prevent stroke, researchers must continue to study the associated cellular mechanisms in
order to discover new ways to mitigate brain damage once a stroke has occurred.
The primary objectives of this introduction are: (A) to summarize the
pathophysiology of stroke, highlighting excitotoxicity and the inflammatory response; (B)
discuss different sources of calcium entry and their implications for excitotoxicity; (C)
highlight the role of CaMKII and its subsequent activity; (D) introduce chemokines; (E)
discuss the potential link between CaMKII and chemokines; and (F) list the specific aims and
outcomes.
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Pathophysiology of stroke
At the gross level, strokes are generally caused by a vascular blockage or a
hemorrhage which limits blood supply to a given brain area. This infarction translates to a
loss of oxygen/glucose and results in a complex pathophysiological state; the ischemic core
suffers from hypoxia, after which cell death is imminent—either by mechanisms of apoptosis
or by necrosis (Deb et al., 2010). Necrotic cell death leads to release of cellular contents,
including glutamate, which may be toxic to cells in the surrounding area (referred to as the
penumbra) that were not directly affected by the ischemic event. In addition to excitotoxicity,
the penumbra is subjected to potentially deleterious effects arising from ionic imbalances and
activation of inflammatory pathways. However, cell death in the penumbra is considered
secondary to the stroke itself and may be preventable through early interventions.
Excitotoxicity
The term “excitotoxicity” was first coined by Olney (1969), following the observation
that over-excitation of neurons with glutamate results in their death. Since then, many of the
underlying mechanisms have been elucidated. These include rises of intracellular calcium
mediated by calcium permeable ion channels; specifically, NMDA receptors (Tymianski,
Charlton & Carlen, 1993), and to a lesser extent L-type voltage gated calcium channels (LVGCCs; Brewer et al., 2007; Stanika et al., 2012).
In normal excitatory conditions, increased intracellular calcium activates a multitude
of pathways, notably the calcium/calmodulin (CaM)-dependent kinase II (CaMKII) signaling
cascade which mediates learning and memory through mechanisms of LTP and LTD
(Lisman et al., 2002). In hyper-excitatory conditions, such as those following stroke, an
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increase of intracellular calcium activates CaMKII, which is believed to participate in a
cascade that can increase damage resulting from excitotoxic events (see Coultrap et al.,
2011). For instance, CaMKII may increase and prolong calcium overload by increasing
cation conductance of AMPARs (Liu & Zukin, 2007), L-VGCCs (Grueter et al., 2006), and
acid sensing ion channels (Gao et al., 2005); thus, enhancing the overexcited state and
potentially exacerbating cell death. However, some downstream targets of CaMKII may
promote cell survival including phosphorylation and inhibition of nitric oxide synthase
(Osuka et al., 2002), insertion of inhibitory GABAA receptors (Mardsen et al., 2010), and
activation of Ras/ERK (Illario et al., 2003). These opposing actions of CaMKII may be
triggered by different sources of calcium, and raise the possibility that the most effective
treatment for stroke might be one that inhibits detrimental effects but enhances the
neuroprotective effects of CaMKII.
NMDA receptors have been targets of intervention following stroke by inhibitory
drugs which block downstream pathway activation, however these interventions have been
largely unsuccessful when tested in humans (Villman & Becker, 2007; Lau & Tymianski,
2010). Alternatively, inhibition of CaMKII has been shown to enhance cell survival
following high glutamate exposure if inhibition follows the stimulus and is short lasting
(Vest et al., 2010); however, CaMKII inhibition results in cell death if inhibition is greater
than four hours in duration (Ashpole et al., 2012).
Inflammatory response
The inflammatory response pathway induces release of signaling molecules, termed
chemokines, in areas that are affected by traumatic events such as stroke or blunt force

4
trauma (Smith, 2013). Acute exposure to chemokines is intended to lead pro-inflammatory
response cells to the area of trauma, but sustained chemokine exposure to nearby neurons
results in cell death (Shepherd et al., 2012). Specifically, prolonged CXCR4 activation by
CXCL12 (formerly referred to as SDF-1alpha) has been shown to result in increases of cell
death in culture. CXCL12 binds to its receptor CXCR4, which is a G-protein coupled protein.
Upon binding of a ligand, CXCR4 triggers release of calcium from intracellular stores and
the possible activation of CaMKII (Shakiryanova et al., 2011; McCord et al., 2013). Thus,
CXCR4 activation may activate CaMKII following ischemia.

Calcium sources
Calcium influx into the cytosol is a highly regulated process that allows for calcium
to act as a reliable signaling molecule responsible for the activation of a multitude of
pathways. Extracellular concentrations of calcium are on the order of 10-3 mM while
intracellular concentrations 10-7 mM are several orders of magnitudes lower. While there are
many possible modes for intracellular Ca2+ to become elevated, three particular mechanisms
are of interest to excitotoxicity and chemokine-activity: 1) influx through the NMDA-type
glutamate receptor; 2) influx through L-type voltage dependent calcium channels; and 3)
release from intracellular stores.
NMDA receptors
The primary excitatory neurotransmitter in the mammalian central nervous system is
the amino acid, L-glutamate. Glutamate acts on both ionotropic glutamate receptors (iGluRs)
and metabotropic glutamate receptors. Three distinct types of iGluRs are present in the CNS:
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1) N-methyl-D-aspartate (NMDA) receptors; 2) α-amino-3-hydroxy-5-methyl-4isoxazolepropionic acid (AMPA) receptors; and 3) kainate receptors. Upon activation by
glutamate AMPA receptors are primarily K+ and Na+ permeable and kinetically characterized
by their rapid activation and desensitization (1-10 ms). NMDA receptors require glutamate,
glycine, and a partially depolarized environment to dislodge a Mg2+ ion block to be activated,
and are thus thought of as “coincidence detectors” (Yuste et al., 1999). NMDAR activation
and desensitization occur on a 10-100 ms timeline and while active, NMDARs are permeable
to cations, most notably Ca2+. Activation kinetics and calcium permeability are dependent on
the subunit composition of any given NMDAR. In cortex, NMDARs are heterotetramers
described as a dimer-of-dimers, requiring two dimers each with an obligatory glycineactivated GluN1 subunit and a glutamate-activated GluN2 (A-D) subunit.
Influx of Ca2+ through NMDARs results in the activation of calcium dependent
signaling pathways, some contribute to excitotoxicity and others contribute to
neuroprotective mechanisms (Arundine et al., 2003). This contribution is currently believed
to depend on the subunit composition of NMDARs—evidence currently indicates that
GluN2B-containing NMDARs contribute pro-death signals while GluN2A-containing
NMDARs contribute pro-survival signals (Mony et al., 2009). It appears this is a least
partially due to the specific characteristics of the GluN2B C-tail. The long 2B-tail allows for
significant interactions with CaMKII (Bayer et al., 2006), which may situate CaMKII in a
way that over-activates the kinase and sets many cell-death pathways in motion (Martel et al.
2010). Currently, GluN2B-containing NMDARs are the target of allosteric modulators for
potential therapeutic benefits related to excitotoxicity (Mony et al.).
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As mentioned previously, drugs targeting NMDA receptors have been utilized as an
intervention following stroke by, however these interventions have been largely unsuccessful
when tested in humans (Villman & Becker, 2007; Lau & Tymianski, 2010). For example,
derivatives from known negative allosteric modulators (i.e., ifenprodil), have failed to
produce decreases in stroke related cell death in clinical trials (Tahirovic et al., 2008). This
lack of effect may in part be due to the fact that additional routes of calcium influx beyond
NMDARs continue to activate pro-death calcium-dependent pathways. The next section
examines one of these alternative routes of Ca2+ influx.
Voltage gated calcium channels
L-type VGCC’s are calcium permeable channels that are voltage dependent. Their
activation is known to affect secretion of neurohormones and neurotransmitters, gene
expression, mRNA stability, synaptic efficacy, and the activity of other ion channels
(Lipscombe et al., 2004). More importantly to the current study, they have also been
implicated in ischemic-induced neuronal injury and neuronal survival (Stanika et al., 2012).
L-VGCCs activate at voltages that typically result in depolarization of the cell
(Lipscombe et al., 2012). Generally, this occurs following the large cation influx that is
mediated by NMDARs, however in ischemic conditions, it is possible that contributions from
AMPARs and acid sensing ion channels are enough to induce VGCC activation. This
calcium influx may then subsequently activate CaMKII (Rose et al., 2009). This will be
important to consider when evaluating the model of cell death that is induced by sustained
chemokine signaling.
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Intracellular calcium stores
In addition to external-to-internal calcium conductance to increase cytoplasmic
calcium, neurons can release calcium from their own intracellular stores in the endoplasmic
reticulum (ER). One mechanism that induces the release of intracellular calcium is the
activation of inositol triphosphate (IP3) receptors. In chemokine signaling, the activation of
chemokine receptors induces activity that creates IP3, which then serves to activate IP3
receptors in the ER (Murdoch and Finn, 2000). Importantly, release of intracellular calcium
has been demonstrated to result in activity of CaMKII in some conditions (McCord et al.,
2013).

Calcium dependent pathways
CaMKII
CaMKII is a dodecameric serine/threonine protein kinase that is ubiquitously
expressed throughout the brain comprising ~2% of total protein (Miller & Kennedy, 1995).
Both the α and β form of CaMKII are implicated in regulating many learning and memory
processes (see Coultrap et al., 2012), although through different mechanisms (Okamoto et al.,
2008). CaMKII activity is triggered by calcium-bound-calmodulin (Ca2+/CaM) following the
elevation of intracellular calcium. Ca2+/CaM binding to CaMKII induces a conformational
change exposing multiple phosphorylation and substrate binding sites; this conformational
change also allows the subunit to bind ATP and phosphorylate substrates (Figure 1; Meyer et
al., 1992). CaMKII can autophosphorylate at multiple sites in its regulatory domain,
including threonine 286 (T286); T286 phosphorylation occurs between the autoinhibitory and
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substrate binding sites, which keeps the subunit locked open and active if intracellular Ca2+
levels drop and CaM dissociates (termed autonomy) (Colbran et al., 1989; Bayer et al.,
2001). CaMKII translocation to synapses is enhanced following T286 phosphorylation
(Strack et al., 1997) however, it is not necessary (Shen & Meyer, 1999). Synaptic
translocation of CaMKII allows it to binds and/or phosphorylate numerous substrates that are
involved in learning and memory, as well as ischemia-induced cell death (Coultrap et al,
2011; 2012). Once Ca2+/CaM has dissociated from the CaM binding site, T305/306 “burst”
autophosphorylation can occur; inhibiting further Ca2+/CaM binding and rendering the kinase
inactive (Colbran & Solderling, 1990). In this state, CaMKII can no longer phosphorylate
any proteins, and thus may help decrease any activation of CaMKII-dependent cell-death
pathways.
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A

Figure 1. Cartoon depiction of CaMKII. A. Ribbon structure of CaMKII dodecamer. The
entire enzyme is around 120Å wide and 60Å thick (Ribbon animation; Rosenberg et al.,
2005). B. Bubble structure of inactivated and activated kinase demonstrating the
conformational change induced by Ca2+/CaM exposing the phosphorylation sites. Each
CaMKII subunit consists of three domains: the C-terminal association domain, which binds
to neighboring subunits; the regulatory domain, which includes the majority of the known
phosphorylation sites, as well as the CaM binding autoinhibitory domain; and the ATP
binding N-terminal catalytic domain (Rosenberg et al., 2005; Bubble structure from Rellos et
al., 2010).
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Due to high glutamate levels, CaMKII translocation to the synapse is observed
following excitotoxic insults (Vest et al., 2010). As noted earlier, several substrates are
targeted by CaMKII following excitotoxic insults, some of which are thought to induce cell
death and while others promote survival (Coultrap et al, 2011). One of the primary targets of
CaMKII following ischemia is the GluN2B subunit of the NMDA receptor which is thought
to be cell-death related; this is due in part to the fact that when CaMKII is bound to GluN2B,
it will remain in a locked, open state and may phosphorylate cell-death inducing substrates
(Bayer et al., 2001; 2006; Barria et al., 2005). Additional death inducing targets include ion
channels such as AMPARs (Liu & Zukin, 2007), L-VGCCs (Grueter et al., 2006), and acid
sensing ion channels (Gao et al., 2005); targeting of these channels are thought to enhance
the overexcited state through influx of cations and exacerbate cell death.
Pro-survival targets include: phosphorylation and inhibition of nitric oxide synthase,
which would otherwise induce oxidative stress and eventually induces apoptosis (Osuka et
al., 2002); insertion of inhibitory GABAA receptors, which allows for the influx of anions to
counteract the influx of cations (Mardsen et al., 2010); activation of Ras/ERK which serves
to counteract apoptosis related phosphorylation (Illario et al., 2003, El Gaamouch et al.,
2012); and activation of cAMP response element-binding (CREB), which binds to CRE and
increases gene transcription of pro-survival genes (Wheeler et al., 2008).
Due to the number of cell-death causing targets, inhibiting CaMKII activity has been
studied as a means to reduce cell death following stroke (Vest et al. 2010; Ashpole et al.,
2011). In several studies, inhibition of CaMKII activity following stroke with potent
inhibitory peptides has resulted in the survival of neurons in culture, as well as decreased
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infarct size in rodent models of stroke (Coultrap et al., 2011; Ashpole & Hudmon, 2011).
However, prolonged inhibition of CaMKII lasting >6 hours appears to be detrimental to
neurons (Ashpole & Hudmon, 2011). One goal of the current study is further investigation
into CaMKII inhibition following chemokine and glutamate induced CaMKII activity.

Inflammation Response
In addition to excitotoxic pathways, inflammatory response pathways become
activated following ischemia. Leukocyte influx and activation of microglia are initial phases
of the inflammatory response (Becker, 1998). In order for leukocytes and microglia to
migrate to the affected area following stroke, they chemotax along high concentration
gradients of chemotactic cytokines, or chemokines (Gouwy et al., 2004).
Chemokines
Chemokines are signaling proteins released from neurons and glia that induce
chemotaxis from nearby inflammatory response cells. However, they also directly couple
neurons through binding of metabotropic chemokine receptors (Meucci et al., 1998). Four
distinct types of chemokines exist: C, CC, CXC, and CX3C, named for the characteristic
cysteine residue at the N-terminal region of the chemokine (Fernandez et al., 2002). Here, I
will focus on the CXC-type because of their implication in the death of neurons as a result of
stroke.
Following stroke, chemokine expression (CXCL12, specifically) is upregulated in
the penumbra both by glia and neurons (Hill et al., 2004). This upregulation of CXCL12 is
likely intended to bind to CXC-receptors (CXCRs) on microglia as a chemotactic signal to
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inflammatory response cells, however CXCRs are also present in neurons (Meucci et al.,
1998). Activation of chemokine receptors by chemokine ligands is important during
development for helping to control axonal migration; additionally, CXCL12 may act as a
neuromodulator in mature cells (Guyon and Nahon, 2007).
Chemokine receptors
In neurons, CXC-receptors are G-protein coupled receptors with 7 transmembrane
domains (Fernandex et al., 2002). The specific receptor for CXCL12 is CXCR4. CXCR4 is
predominately distributed throughout the somatodendritic region of hippocampal neurons
(Shepherd et al., 2012). Upon binding of a ligand, the G-protein creates IP3 which
translocates and triggers the release of calcium from intracellular stores (Murdoch and Finn,
2004). This calcium release can then activate CaM and the associated calcium dependent
processes previously discussed.
In pathological states, CXCL12 may be both protective and detrimental following
activity that mimics stroke (Shepherd et al., 2012). Specifically, CXCR4 activation by
CXCL12 has been shown to increases cell death following prolonged activation (Figure 2).
In addition, it has been shown that down-regulation of CXCR4 with the anti-inflammatory
drug dexamethasone is neuroprotective and reduces infarct size in rodent models of
hypoxia/ischemia (Felszeghy et al., 2004). Release of intracellular calcium has been
demonstrated to activate CaMKII following oxidative stress (McCord et al., 2013) thus
indicating the potential role of CaMKII activation in CXCR4-mediated cell death.
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Figure 2. Sustained CXCR4 signaling. CXCL12 is released from cells in the ischemic
penumbra, this then binds to CXCR4, which is present in hippocampal neurons; prolonged
CXCR4 activation then induces rises in intracellular calcium that combine with
NMDA/VGCC mediated calcium rises to activate CaM. Subsequently, CaM activates
Calcineurin (a protein phosphatase that dephosphorylates substrates) which activates voltage
gated potassium channels subsequently allowing excessive potassium efflux. Following this,
cells become stressed, and the apoptosis pathway is triggered. Not shown is the activation of
CaMKII (Shepherd et al., 2012).
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Proposed model
The proposed model of CXCL12 induced cell death is as follows (from Shepherd et
al., 2012):
1) CXCL12 is released from cells in the ischemic penumbra
2) CXCR4 receptors become activated;
3) Prolonged CXCR4 activation (3 hour) induces rises in intracellular calcium that
combine with NMDA/VGCC mediated calcium rises to activate CaM.
4) CaM activates Calcineurin (a protein phosphatase that dephosphorylates
substrates) which activates voltage gated potassium channels and subsequently
allows excessive potassium efflux;
5) Cells undergo mitochondrial dysfunction and the apoptosis pathway is activated.

In contrast to prolonged CXCL12 exposure, acute CXCL12 exposure (30 min)
appears to induce a calcium spike which is mitigated by acute outward potassium
conductance through voltage gated potassium channels. The present study examined if
CXCR4 signaling enhances CaMKII activity that may mediate cell death.
Concentrations of 500 µM glutamate are commonly used as a reliable excitotoxic
stimulus when studying glutamate’s intracellular effects, while concentrations of 100 µM are
used to produce a moderate, excitatory stimulus (Vest et al., 2010; Shen & Meyer, 1999).
Here, I examined if these two different concentrations of glutamate (500 µM and 100 µM)
interact with the effects of CXCR4 activation (acute and sustained), to produce increased cell
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death or attenuated cell death. The data collected suggests that different calcium sources act
synergistically to increase a detrimental calcium signal.

Specific Aims
This thesis research utilized cultured hippocampal neurons to investigate the role of
CaMKII in CXCL12-dependent cell death. In order to determine the role of CaMKII in the
cellular response to CXCL12, immunocytochemistry was used to determine the localization
of CaMKII following CXCL12 exposure and subsequent glutamate + glycine exposure.
Specific aims were as follows:
1. Establish cell death ratios following acute and sustained CXCL12 exposure
and a subsequent glutamate + glycine challenge.
2. Establish CaMKII localization patterns following CXCL12 and a subsequent
glutamate + glycine challenge.
3. Inhibit CaMKII activity during CXCL12 pre-exposure and examine if rates of
cell death change following a subsequent glutamate + glycine challenge.
4. Inhibit CaMKII activity during CXCL12 pre-exposure and examine if
CaMKII localization patterns change following a subsequent glutamate +
glycine challenge.
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Chapter 2: Methods

Ethical considerations
All experiments involving the use of rats and the procedures were approved by the
Western Washington University Institutional Animal Care and Use Committee and were in
strict accordance with the Guide for the Care and Use of Laboratory Animals described by
the National Institutes of Health.

Primary culture of rat hippocampal neurons
Hippocampal neurons from rat embryos were isolated and cultured as described by
Kaech and Banker (2006). Hippocampi from Sprague-Dawley rat embryos of either sex were
removed at embryonic day 18 and incubated in Hank’s Buffered Saline Solution (HBSS;
Gibco) with trypsin (1 mg/ml; Gibco) for 15 min at 37°C. Hippocampi were then washed six
times with HBSS, followed by trituration to dissociate cells. Cells were then counted and
plated onto poly-D-lysine-coated (MW > 100,000; Sigma) glass coverslips at a density of
150,000 cells per 60 mm dish in Neurobasal medium containing (Gibco) B27 (Gibco), 0.6
mM glutamine and penicillin/streptomycin. The cells were incubated in a 5% CO2 incubator
at 37°C for 2–4 h, after which the coverslips were transferred to a previously prepared dish
containing a glial feeder layer (as described by Kaech and Banker) in
Neurobasal/B27/glutamine media and maintained at 37°C in a 5% CO2 incubator. One-third
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of the medium was exchanged weekly and APV was added twice weekly. All experiments
were performed on neurons that were cultured for 14–16 days in vitro (DIV).

Experimental treatment
Coverslips were removed from their glial dishes and briefly washed in extracellular
solution (ECS; in mM: 168 NaCl, 2.4 KCl, 10 HEPES, 10 D-glucose, 1.3 CaCl2, 1.3 MgCl2,
pH 7.3) and placed face up. 100µL of 100nM CXCL12 (Peprotech; and produced by Dr.
John Antos, WWU Chemistry Department) in ECS was applied to each coverslip for either
30 minutes (acute treatment) or 3 hours (sustained treatment). Subsequently, 500µM or
100µM glutamate + 10 µM glycine in ECS was applied for 1 min. The glutamate + glycine
solution was then removed and replaced with ECS and incubated for an additional 15 min or
60 min. Cells were treated with a cell death assay and immunocytochemistry (ICC) at the end
of their prescribed incubation time.
To assess the role of CaMKII, the CaMKII/CaM inhibitor peptide SC3037 (Santa
Cruz Biotechnology; Sequence: LKKFNARRKLKGAILTTMLA ) and the CaMKII inhibitor
SC3039 (Santa Cruz Biotechnology; Sequence: MHRQEAVDCLKKFNARRKLKGA) were
used (final concentration: 1 µM) to inhibit the activity of CaMKII during the CXCL12
incubation and glutamate + glycine stimulations. Peptides inhibitors were co-administered
with CXCL12 and remained until washout of glutamate + glycine. See Appendix D for
model depicting action of SC3037 and SC3039.
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For controls, neurons were incubated in ECS for the corresponding duration of the
experiment and were then treated with the same cell death assay followed by the ICC
protocol.

Cell death assay and immunocytochemistry
Following experimental treatment, neurons were incubated for 15 min at room
temperature (RT) in fixable viability dye eFluor-660 (eBioscience) as a marker of
compromised cells destined to dye, immediately followed by 12 min RT incubation in 37°C
4% paraformaldehyde to permanently fix cells. Cells were then permeablized in 0.25%
Triton X, and blocked in 10% bovine serum albumin for 30 min at 37°C. Primary antibodies
mouse monoclonal anti-CaMKII IgG1 (1:1000, Abcam) and mouse monoclonal anti-PSD95
IgG2a (1:1000, Abcam), were applied at RT overnight on a shaker. Secondary antibodies
Alexa Flour 568-conjugated anti-mouse IgG1 (1:800) and Alexa Flour 488-conjugated antimouse IgG2a (1:400) were applied for 45 min at 37°C. Cells were mounted on glass slides in
DAPI mounting medium (Southern Biotechnology) and sealed with nail polish. Slides were
imaged using an Olympus IX-80 inverted microscope with epifluorescence. All images were
collected with a CCD camera (Hamamatsu) using Metamorph basic software (Molecular
Devices, Inc.). See Appendix A and B for sample images.

Data analysis
To assess cell death, all groups were imaged with a 20X objective and three channels
were collected; DIC, CY5 (to image the cell death marker), and DAPI (to image nucleus-
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bound DAPI). Each image yielded 10-60 neurons; each coverslip was imaged in 5-10
different locations. To analyze each image, DAPI stained cells were counted to get the total
cell count and CY5 stained cells were counted to get the dead cell count. Cell death ratios
were calculated.
To assess CaMKII localization, all images were collected with a 40X oil objective
and three channels were collected; DIC, FITC (to image PSD95), Texas Red (to image
CaMKII). Five to ten neuron images per coverslip were collected. To quantify CaMKII colocalization with PSD95, the ImageJ (NIH) plug-in JaCOP was used to measure and compare
the degree of overlap between CaMKII puncta and PSD95 puncta.
Data were analyzed using SPSS (IBM) with a one-way ANOVA to compare means
within each group. Dunnett’s post-hoc test was used to compare means in each cell death
condition to the CXCR4 condition. REGW-Q post-hoc test was used to compare all CaMKII
conditions to each other.
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Chapter 3: Results

Glutamate + glycine results in cell death
Exposure to glutamate + glycine significantly increased cell death F (4, 62) = 14.81, p
< .0001. REGW-Q post-hoc was used to compare all means and keep a family-wise alpha of
.05. REGW-Q post-hoc comparisons revealed that ECS, and the two 100µM were not
significantly greater than ECS. However, 15 min post 500µM glutamate + glycine showed
significant increases in cell death, while 60 mins post 500µM glutamate + glycine showed
significantly more cell death than at 15 min post 500µM glutamate + glycine (Figure 3).
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Figure 3. Glutamate + Glycine viability dye ratios. * indicates significant comparison to
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comparisons.
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CXCL12 enhances glutamate induced cell death
A one-way ANOVA revealed a main effect of acute CXCL12 exposure and glutamate
+ glycine on cell death, F (5, 63) = 22.04, p < .0001. Dunnett’s post-hoc test comparing
experimental treatments to ECS control revealed that acute CXCL12 exposure had no effect
on cell death (p > .05). However, cell death levels following 100µM and 500µM glutamate +
glycine visualized 15 mins and 60 mins post-treatment were significantly higher than
controls (p < .05) (Figure 3a).
A one-way ANOVA revealed a main effect of sustained CXCL12 exposure and
glutamate + glycine on cell death, F (5, 75) = 103.608, p < .001. Dunnett’s post-hoc test
comparing experimental treatments to ECS control revealed that acute CXCL12 exposure
had a significant increase on cell death (p < .05). Interestingly, cell death levels following
100µM and 500µM glutamate + glycine visualized 15 min- and 60 mins post-treatment were
significantly higher than glutamate + glycine controls (p < .05) (Figure 3b).
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Figure 4. CXCL12 viability dye ratios. * indicates significant Dunnett’s post-hoc
comparison with ECS as control; p < .05 for all comparisons.
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SC3037 attenuates glutamate induced cell death following CXCL12 exposure
A one-way ANOVA revealed a main effect of acute CXCL12 exposure combined
with the CaMKII inhibitor SC3037 and glutamate + glycine on cell death, F(5, 51) = 4.256, p
= .002. Dunnett’s post-hoc test comparing all treatments to CXCL12 + SC3037 revealed that
acute exposure of the chemokine with inhibitor had no effect on cell death compared to ECS
(p > .05). Additionally, cell death levels following 100µM and 500µM glutamate + glycine
visualized 15 min-post treatment and 100µM 60 mins post-treatment were not higher than
ECS controls. Interestingly, 500µM glutamate + glycine exposure visualized 60 mins
following acute CXCL12 + SC3037 resulted in significantly higher cell death (p < .05)
(Figure 4a).
A one-way ANOVA revealed a main effect of sustained CXCL12 + SC3037 exposure
and glutamate + glycine on cell death, F (5, 44) = 4.523, p < .003. Dunnett’s post-hoc test
comparing all treatments to CXCL12 + SC3037 revealed that sustained CXCL12 + SC3037
exposure had a significant increase on cell death compared to ECS controls (p < .05).
However, cell death levels following 100µM and 500µM glutamate + glycine visualized 15
min-post treatment and at 60 mins post-treatment were not significantly different than
CXCR4 + SC3037 (p > .05) (Figure 4b).
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SC3039 interferes with CXCL12 induced cell death
A one-way ANOVA revealed a main effect of acute CXCL12 exposure combined
with the CaMKII inhibitor SC3039 and glutamate + glycine on cell death F (5, 84) = 4.284, p
= .002. Dunnett’s post-hoc test comparing all treatments to CXCL12 + SC3039 revealed that
acute exposure had no effect on cell death compared to ECS (p > .05). Additionally, cell
death levels following 100µM and 500µM glutamate + glycine visualized 15 min-post
treatment and 100µM 60 mins post-treatment were not higher than ECS controls. 500µM
glutamate + glycine exposure visualized 60 mins following acute CXCL12 + SC3039
resulted in significantly higher cell death (p < .05) (Figure 5a).
A one-way ANOVA revealed a main effect of sustained CXCL12 + SC3037 exposure
and glutamate + glycine on cell death F (5, 84) = 7.906, p < .0001. Dunnett’s post-hoc test
comparing all treatments to CXCL12 + SC3039 revealed that sustained CXCL12 + SC3039
exposure had a significant effect on cell death compared to control (p < .05). Additionally,
cell death levels following 100µM and 500µM glutamate + glycine visualized 15 min-post
treatment and at 60 mins in the 100µM post-treatment were not significantly different than
CXCR4 + SC3039 (p > .05). However, 500µM glutamate + glycine exposure visualized 60
mins following acute CXCL12 + SC3039 resulted in significantly higher cell death (p < .05)
(Figure 5b).
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CaMKII synaptic translocation is induced by CXCL12 and glutamate
A one-way ANOVA revealed a main effect of acute CXCL12 exposure and glutamate
+ glycine on synaptic CaMKII translocation, F (5, 43) = 10.368, p < .001. REGW-Q post-hoc
was used to compare all means and keep a family-wise alpha of .05. REGW-Q revealed that
all exposure conditions showed significantly greater synaptic CaMKII than ECS as measured
by degree of colocalization with the synaptic marker PSD (Figure 7a).
A one-way ANOVA revealed a main effect of sustained CXCL12 exposure and
glutamate + glycine on synaptic CaMKII translocation, F (5, 39) = 4.039, p < .001. REGW-Q
revealed that all exposure conditions showed significantly greater synaptic CaMKII than
ECS (Figure 7b).
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for all comparisons.

30
SC3037 inhibits CaMKII synaptic translocation
A one-way ANOVA revealed no main effect of acute CXCL12 exposure combined
with the CaMKII inhibitor SC3037 and glutamate + glycine on CaMKII synaptic
translocation F (5, 74) = 1.211, p = 1.211 (Figure 8a).
A one-way ANOVA revealed no main effect of sustained CXCL12 + SC3037
exposure and glutamate + glycine on synaptic CaMKII translocation F (5, 64) = 1.685, p =
.151 (Figure 8b).
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SC3039 allows CaMKII synaptic translocation
A one-way ANOVA revealed a main effect of acute CXCL12 exposure combined
with the CaMKII inhibitor SC3039 and glutamate + glycine on synaptic CaMKII, F (5, 101)
= 5.47, p < .001. REGW-Q revealed that acute CXCL12 exposure and visualization 15 min
post- glutamate + glycine had significantly increased PSD/CaMKII ratios compared to ECS,
while the 60 min conditions did not (Figure 9a).
A one-way ANOVA revealed a main effect of sustained CXCL12 + SC3039 exposure
and glutamate + glycine on cell death F (5, 96) = 4.73, p = .001. REGW-Q revealed that
sustained CXCL12 + SC3039 exposure and visualization 15 min post- glutamate + glycine
had significantly increased PSD/CaMKII ratios compared to ECS, while the 60 min
conditions were significantly lower than CXCL12 + SC3039 (Figure 9b).

PSD/CaMKII Synaptic Ratio

33

1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0

*

PSD/CaMKII Synaptic Ratio

ECS

1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0

CXCL12
SC3039

*

*

*

15m 100
15m 500
60m 100
SC3039
SC3039
SC3039
Acute CXCL12 + SC3039

60m 500
SC3039

*
#

ECS

CXCL12 15m 100
15m 500
60m 100
SC3039
SC3039
SC3039
SC3039
Sustained CXCL12 + SC3039

60m 500
SC3039

Figure 9. CXCL12 + SC3039 PSD/CaMKII synaptic ratios. * indicates significant difference
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post-hoc comparisons.
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Chapter 4: Discussion

Acute CXCL12 exposure and the corresponding activation of CXCR4 was not
harmful to cells, as indicated by uptake of cell viability dye, while sustained exposure
resulted in cell death rate of approximately 25% (Figure 4a). These results agree with
previous observations of cell death rates following CXCL12 exposure of different time
durations (Shepherd et al., 2012). Additionally, both acute and sustained CXCL12 exposure
induced synaptic translocation of CaMKII, suggesting CXCL12 induced a rise of
intracellular calcium sufficient enough to induce CaMKII translocation (Figure 7a).
When cells were exposed to an excitotoxic stimulus (500µM glutamate + 10µM
glycine) following acute CXCL12 exposure, cell death rates rose significantly (Figure 4a).
When cells were exposed to a lower, physiologically relevant glutamate stimulus (100µM
glutamate + 10µM glycine), cell death rates were similar to those seen following the high
concentration excitotoxic stimulus (Figure 4a). Cell death was not observed following a brief
sub-maximal glutamate stimulus without CXCL12 pre-exposure (100µM glutamate + 10µM
glycine; Figure 3), suggesting that CXCL12 exposure may interfere with the cells ability to
buffer against a large calcium influx that results from glutamate + glycine activation of
NMDA receptors. Interestingly, following the glutamate + glycine exposure, rates of cell
death seemed to plateau by 15 minutes, as neurons examined for cell death at 60 minutes did
not show marked increases above the 15 minute levels (Figure 3). This may suggest the cell
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death caused by this mechanism occurs rapidly in those cells that die, while cells that
survived were still able to buffer against the calcium spike (Ankarcrona et al., 1995).
When cells were challenged with glutamate + glycine following sustained CXCL12
exposure, cell death rates were again higher than expected from both excitotoxic and
physiologically relevant concentrations (Figure 4b). However, cell death rates did not plateau
after 15 minutes as they did following the acute condition, instead the cell death rate was
increased at 60 minutes, suggesting that the brief stimulus may activate slower apoptotic cell
death mechanisms. Nicolai et al. (2010) previously demonstrated that prolonged CXCL12
exposure downregulates NMDA receptors and is neuroprotective when cells were
subsequently challenged to a sustained 100 µM NMDA stimulus 24 hours later. However,
Nicolai et al. were investigating the role of a lower, more physiologically typical level of
CXCL12 exposure (20nM CXCL12 compared to 100nM CXCL12 used here) that could be
expected in non-ischemic conditions. In this case, CXCL12 down regulates NMDAR gene
expression, and in order to see protective effects due to decreased NMDARs, the NMDA
stimulus was not administered until 24 hours following initial CXCL12 exposure (Nicolai et
al., 2010). It is possible that the CXCL12 paradigm used in the current study also enhances
NMDAR downregulation, however it may not occur early enough to protect from a large
glutamate challenge within 3 hours.
The CaMKII-derived peptide inhibitor of CaM, SC3037, was able to completely
inhibit synaptic translocation of CaMKII following both acute and sustained CXCL12
exposure, as well as following a subsequent application of glutamate (Figure 8). This
corresponded to inhibition of cell death following acute CXCL12 exposure and the lower,
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physiologically relevant glutamate stimulus (Figure 5a). However, the rate of cell death
observed 60 minutes after the application of the excitotoxic stimulus (500µM) was greater
than CXCR4 activation alone (p < .05). This suggests that inhibition of CaM decreases the
CXCL12-induced enhancement of glutamate-induced cell death; however, CaM acts on a
multitude of substrates and the inhibition of CaMKII translocation is likely only one of the
many effects that CaM inhibition induced.
Inhibition of CaM during sustained CXCL12 exposure did not completely inhibit
CXCL12-induced cell death, although it appears to be partially attenuated compared to
CXCL12 exposure alone (Figure 5b). This is in agreement with Shepherd et al. (2012), who
saw a significant reduction in cell death (but not a return to baseline) through the inhibition
of calcineurin, a Ca2+/CaM dependent phosphatase (Figure 2). It may be that the slight
reduction in cell death seen here was due to a reduction in calcineurin activity. Additionally,
inhibition of CaM reduced cell death observed following additional glutamate stimulus.
Together, these data suggest that inhibition of CaM is not sufficient to completely inhibit
CXCL12-induced cell death, although it does protect from cell death induced by subsequent
glutamate signaling.
The inhibition of CaMKII catalytic activity with the CaMKII-derived peptide
inhibitor of CaMKII, SC3039 greatly reduced the rate of cell death following acute CXCL12
exposure and the subsequent glutamate + glycine challenge, suggesting that the inhibition of
CaMKII activity protects from this particular excitotoxic stimulus (Figure 6).
SC3039 did not inhibit translocation of CaMKII to the synapse (Figure 9). This was
expected because of the nature in which SC3039 inhibits CaMKII. SC3039 binds to the s-site
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and a portion of the t-site of the Ca2+/CaM bound CaMKII, inhibiting the ability for ATP
binding and subsequent autophosphorylation and autonomy of CaMKII (Bayer et al., 2001;
Appendix D). When acute CXCL12 + SC3039 incubated cells were subsequently treated to
toxic (500µM) and sub-toxic (100µM) glutamate levels, CaMKII synaptic translocation
persisted and was still present at 15 minutes post-treatment. Interestingly, when visualized 60
minutes post glutamate + glycine application, CaMKII synaptic translocation no longer
significantly elevated compared to CXCL12 alone. This may have been due to a weak
CaMKII interaction with the GluN2B tail, which would allow CaMKII to dissociate and
return to the dendrite (Bayer et al., 2006). Another possible explanation is that SC3039 was
degraded by proteolysis during the 60 minute incubation (Otmakov et al., 1997) which
subsequently allowed ATP binding and burst T305/306 phosphorylation in the absence of
Ca2+/CaM. Burst phosphorylation shuts down CaMKII and induces a return of synaptic
CaMKII to baseline (Strack, 1997). In either case, it seems CaMKII synaptic translocation
alone is not necessary for CXCL12 enhancement of glutamate + glycine induced cell death.
The pattern of CaMKII synaptic translocation following sustained CXCL12 +
SC3039 exposure followed a similar pattern of translocation as the acute condition. Again,
synaptic accumulation of CaMKII occurred following CXCL12 + SC3039 and glutamate
exposure; however, cell death was notably attenuated compared to CXCL12 + glutamate
exposure without the CaMKII inhibitor, as well as excitotoxic 500µM glutamate + glycine
exposure without CXCL12 exposure (Figure 3). This further supports that inhibition of
CaMKII preferentially inhibits glutamate induced cell death following a prolonged exposure
to CXCL12.
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The role of CaMKII in post-CXCL12 ischemic cell death may help explain why
simple glutamate blocking drugs do not always reduce cell death following ischemic attacks
(Lau & Tymianski, 2010). Glutamate antagonists are typically only partial antagonists,
however the data here suggest that even low glutamate activity can cause cell death following
high CXCL12 exposure that may be present following global ischemia. Indeed, work with
potent CaMKII-specific inhibitors, with stronger affinity and better specificity (Vest et al.,
2007) than the peptides used here, have been able to significantly reduce glutamate-induced
cell death, even when administered after a glutamate insult (Vest et al., 2010; Ashpole et al.,
2011).
More recently, McCord et al. (2013) demonstrated that CaMKII inhibition greatly
reduces activated microglial (AMG) induced cell death. McCord et al. proposed that this cell
death is occurs via a mechanism similar to CXCL12 activated cell death proposed by
Shepherd et al. (2012); i.e., AMG activates CaMKII through intracellular calcium release,
and subsequently CaMKII facilitates insertion of Kv2.1 channels which promote excessive
potassium efflux. It is unclear if the current experiment also inhibited Kv2.1 insertion using
peptide inhibitors, however it is likely one of the processes that was inhibited as CaMKII
phosphorylation of syntaxin is required for Kv2.1 insertion and the detrimental enhancement
of potassium efflux (McCord et al., 2013). In addition, although CaMKII inhibition appeared
to reduce cell death following sustained CXCL12 exposure compared to non-inhibited
conditions, it was not completely attenuated, suggesting CaMKII phosphorylation is
necessary for CXCL12 induced cell death, but not sufficient. Thus, other molecular
mechanisms are likely triggered by CXCL12 exposure/CXCR4 activation which contribute
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to cell death, but inhibition of CaMKII at least partially protects from some of the negative
effects of excitotoxicity.
Several types of CaMKII mutants exist which can help distinguish the substrate
interactions necessary for CXCL12/glutamate + glycine induced cell death. For example,
CaMKII-I205K specifically inhibits GluN2B interaction, but leaves kinase activity intact
(Bayer et al., 2006). This would highlight if the GluN2B interaction is necessary.
Additionally, CaMKII-T286A impairs autonomy but leaves kinase ability intact during the
calcium stimulus (Coultrap et al., 2012); this would demonstrate if CXCL12 cell death can be
initiated by brief activity of CaMKII. Through these experiments, it may be possible to
resolve any specific interactions are required for CXCL12 induced cell death.
Taken together, the current study supports further investigation of CaMKII as a
potential therapeutic target to decrease cell death following global ischemia. Because
CaMKII can act on such a multitude of substrates in the synapse and is important for many
normal functions, including learning and memory, determining how to inhibit only the
specific interaction involved in excitotoxicity-related cell death may be key to utilizing
CaMKII inhibition therapeutically.
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Appendix A

Figure A1. Left: ECS exposed neuron images of CaMKII (red; top), PSD95 (green; middle)
and Overlay (multi; bottom). CaMKII appears very diffuse without stimulation of cells.
Overlay shows that CaMKII is not colocalized to the synaptic marker protein, PSD95. Right:
Acute CXCL12 exposed neuron images of CaMKII (red; top), PSD95 (green; middle) and
Overlay (multi; bottom). CaMKII appears punctate. Overlay shows that CaMKII puncta are
highly colocalized with PSD95.
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Appendix B

Figure B1. Sample immunohistochemistry neurons. Top: Overlay image of ECS images at
20X includes DIC image with DAPI channel and CY5 channel. Blue indicates all cells, red
indicates dead cells. Bottom: Overlay image of acute CXCL12 + Glutamate/Glycine at 15
minutes.
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Appendix C

Figure C1. Schematic depicting the order in which CXCL12 and glutamate + glycine are
applied. CXCL12 is applied, followed by glutamate + glycine. Cells are then fixed after 15 or
60 minutes. Total experiment time range 46 min to 4:01 hours.

51
Appendix D

GluN2B Interaction
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Figure D1. CaMKII regulatory domain is typically autoinhibited by the autoinhibitory
domain (blue). When the autoinhibitory domain is bound by Ca/CaM, the t-site and the s-site
become exposed. This allows for ATP to bind as well as phosphorylation of T286, both of
which can leave the kinase active following the dissociation of CaM (top left). In addition,
GluN2B can bind to the t-site of CaMKII to keep the kinase locked in an open position in the
absence of CaM (top right). In the presence of SC3039, the t-site only remains partially
available for GluN2B interaction, it is unclear if SC3039 allows any GluN2B interaction.
However, SC3039 (orange) occupies the ATP binding domain and the kinase is not
catalytically active (bottom right). In the presence of SC3037, Ca2+/CaM binds SC3037 when
activated; if Ca2+/CaM binds CaMKII, SC3037 can bind CaMKII and inhibit ATP binding.
Figure based on data from Bayer et al. (2001; 2006) and Rosenberg et al. (2005).

